Evidence map›Paper›PMID 37566031›Full record

ArticleCells2023

Genetic Downregulation of the Metabotropic Glutamate Receptor Type 5 Dampens the Reactive and Neurotoxic Phenotype of Adult ALS Astrocytes.

Carola Torazza, Francesca Provenzano, Elena Gallia, Maria Cerminara, Matilde Balbi, Tiziana Bonifacino, Sara Tessitore, Silvia Ravera, Cesare Usai, Ilaria Musante and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 3 countries.

Carola TorazzaDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.
Francesca ProvenzanoDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.
Elena GalliaDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.
Maria CerminaraDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Paolo Daneo, 16132 Genoa, Italy.
Matilde BalbiDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.
Tiziana BonifacinoDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.ORCID 0000-0002-3966-9874
Sara TessitoreDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.
Silvia RaveraDepartment of Experimental Medicine (DIMES), University of Genoa, Via Alberti L.B. 2, 16132 Genova, Italy.ORCID 0000-0002-0803-1042
Cesare UsaiInstitute of Biophysics, National Research Council (CNR), Via De Marini 6, 16149 Genoa, Italy.
Ilaria MusanteUOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Aldamaria PulitiDepartment of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Largo Paolo Daneo, 16132 Genoa, Italy.
Ludo Van Den BoschDepartment of Neurosciences, Experimental Neurology, and Leuven Brain Institute, KU Leuven-University of Leuven, 3000 Leuven, Belgium.ORCID 0000-0003-0104-4067
Paymaan Jafar-NejadIonis Pharmaceuticals, Carlsbad, CA 92010, USA.
Frank RigoIonis Pharmaceuticals, Carlsbad, CA 92010, USA.
Marco MilaneseDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.ORCID 0000-0003-3384-0666
Giambattista BonannoDepartment of Pharmacy (DIFAR), University of Genoa, Viale Cembrano 4, 16148 Genova, Italy.ORCID 0000-0003-3744-5786
University of Genoa · ITIstituto Giannina Gaslini · ITIonis Pharmaceuticals (United States) · USNational Research Council · ITOspedale Policlinico San Martino · ITUniversity of Pisa · ITVIB-KU Leuven Center for Brain & Disease Research · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons (MNs). Astrocytes display a toxic phenotype in ALS, which results in MN damage. Glutamate (Glu)-mediated excitotoxicity and group I metabotropic glutamate receptors (mGluRs) play a pathological role in the disease progression. We previously demonstrated that in vivo genetic ablation or pharmacological modulation of mGluR5 reduced astrocyte activation and MN death, prolonged survival and ameliorated the clinical progression in the SOD1

Indexed as

Amyotrophic Lateral SclerosisNeurodegenerative DiseasesReceptor, Metabotropic Glutamate 5AnimalsAstrocytesDown-RegulationGlutamic AcidMiceMice, TransgenicSuperoxide Dismutase-1Glutamic AcidGrm5 protein, mouseReceptor, Metabotropic Glutamate 5Superoxide Dismutase-1adult mouse spinal cord astrocytesamyotrophic lateral sclerosisGrm5 genetic ablationmGlu5 receptorSOD1G93A mice

Identifiers

PMID37566031
PMCPMC10416852
OpenAlexW4385346910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.